Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOAC Levels Prior to Incision (DALI)
2018-001443-31Phase 4Active
- Sponsor
- Leiden University Medical Center
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dabigatran, rivaroxaban and apixaban in venous thromboembolism (VTE) and Atrial fibrillation (AFib) (3 arms), sponsored by Leiden University Medical Center. Primary endpoint: Preoperative DOAC plasma level. Started May 2018; status: active.
02
Drugs
dabigatranrivaroxabanapixaban
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2018-001443-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001443-31.